Coherus BioSciences Announces New Employment Inducement Grants
May 03 2022 - 9:44PM
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq:
CHRS), today announced that effective April 27, 2022, the
compensation committee of the Company’s board of directors granted
options to purchase an aggregate of 240,000 shares of the common
stock of the Company to 13 newly hired employees with a per share
exercise price of $9.28, the closing trading price on the grant
date. Two newly hired Vice Presidents were each granted options to
purchase 45,000 shares, and one newly hired Vice President was
granted options to purchase 50,000 shares. Ten non-officer
employees were granted options to purchase an aggregate of 100,000
shares.
The stock options were granted pursuant to the Coherus
BioSciences, Inc. 2016 Employment Commencement Incentive Plan,
which was approved by the Company’s board of directors in June 2016
under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity
grants to induce new employees to enter into employment with the
Company.
Coherus BioSciences Contact Information:
IR Contact
McDavid Stilwell
Coherus BioSciences, Inc.
IR@coherus.com
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024